The Telegraph covered our latest study on obesity, which showed that individuals with a genetic risk score for high BMI, calculated using Genomics’ proprietary polygenic risk scores (PRS), were 10 times more likely to develop obesity later in life - even at the same activity levels and calorie intake.

Our research shows that those at high genetic risk of obesity will need personalised support to help them stay at, or return to, a healthy weight.

Genomics releases new research showing significant link between genetic risk and obesity

Genomics announces the appointment of David Thornton to the position of President, succeeding Professor Gil McVean, who will join the board as a non-executive Director.

The Times covers a new study that has claimed that thousands of heart attacks and strokes could be prevented by incorporating people’s genetic risk into their standard middle-aged health check. Researchers have identified a suite of genetic changes, affecting 1 in 12 Britons, that significantly raise the chance of suffering heart disease.

Mount Sinai Health System is launching a center that will conduct genetic-based research on undiagnosed medical conditions. The system's Center for Undiagnosed Diseases will open early next year, the latest evidence of the money providers are pouring into genomics. Mount Sinai said Tuesday the center will be home to New York City's first undiagnosed disease network, which connects clinicians across the U.S. conducting this kind of research.

As the conversation around genetic risk testing continues to evolve, it's crucial to address the misconceptions that surround it. This latest article by Genomics' Co-Founder and CEO, Sir Peter Donnelly, discusses the common misunderstandings around genetic risk testing and the untapped benefits it holds for the insurance industry.

The three-year extension expands the range of therapeutic areas and genomic data insights and also explores the use of genomic risk to better define patient subgroups

We are proud to unveil new findings about our Integrated Risk Tool for cardiovascular disease, which has just achieved another significant validation. A recent study led by the University of Leicester, published in the esteemed European Heart Journal, underscores the transformative potential of our tool in early prevention.

The collaboration, across multiple therapeutic areas, will evaluate how polygenic risk scores could be used to improve clinical trial design and efficiency

The Telegraph covered our latest study on obesity, which showed that individuals with a genetic risk score for high BMI, calculated using Genomics’ proprietary polygenic risk scores (PRS), were 10 times more likely to develop obesity later in life - even at the same activity levels and calorie intake.

Our research shows that those at high genetic risk of obesity will need personalised support to help them stay at, or return to, a healthy weight.

Genomics releases new research showing significant link between genetic risk and obesity

Genomics announces the appointment of David Thornton to the position of President, succeeding Professor Gil McVean, who will join the board as a non-executive Director.

The Times covers a new study that has claimed that thousands of heart attacks and strokes could be prevented by incorporating people’s genetic risk into their standard middle-aged health check. Researchers have identified a suite of genetic changes, affecting 1 in 12 Britons, that significantly raise the chance of suffering heart disease.

Mount Sinai Health System is launching a center that will conduct genetic-based research on undiagnosed medical conditions. The system's Center for Undiagnosed Diseases will open early next year, the latest evidence of the money providers are pouring into genomics. Mount Sinai said Tuesday the center will be home to New York City's first undiagnosed disease network, which connects clinicians across the U.S. conducting this kind of research.

As the conversation around genetic risk testing continues to evolve, it's crucial to address the misconceptions that surround it. This latest article by Genomics' Co-Founder and CEO, Sir Peter Donnelly, discusses the common misunderstandings around genetic risk testing and the untapped benefits it holds for the insurance industry.

The three-year extension expands the range of therapeutic areas and genomic data insights and also explores the use of genomic risk to better define patient subgroups

We are proud to unveil new findings about our Integrated Risk Tool for cardiovascular disease, which has just achieved another significant validation. A recent study led by the University of Leicester, published in the esteemed European Heart Journal, underscores the transformative potential of our tool in early prevention.

The collaboration, across multiple therapeutic areas, will evaluate how polygenic risk scores could be used to improve clinical trial design and efficiency

The Telegraph covered our latest study on obesity, which showed that individuals with a genetic risk score for high BMI, calculated using Genomics’ proprietary polygenic risk scores (PRS), were 10 times more likely to develop obesity later in life - even at the same activity levels and calorie intake.

Our research shows that those at high genetic risk of obesity will need personalised support to help them stay at, or return to, a healthy weight.

Genomics releases new research showing significant link between genetic risk and obesity

Genomics announces the appointment of David Thornton to the position of President, succeeding Professor Gil McVean, who will join the board as a non-executive Director.

The Times covers a new study that has claimed that thousands of heart attacks and strokes could be prevented by incorporating people’s genetic risk into their standard middle-aged health check. Researchers have identified a suite of genetic changes, affecting 1 in 12 Britons, that significantly raise the chance of suffering heart disease.

Mount Sinai Health System is launching a center that will conduct genetic-based research on undiagnosed medical conditions. The system's Center for Undiagnosed Diseases will open early next year, the latest evidence of the money providers are pouring into genomics. Mount Sinai said Tuesday the center will be home to New York City's first undiagnosed disease network, which connects clinicians across the U.S. conducting this kind of research.

As the conversation around genetic risk testing continues to evolve, it's crucial to address the misconceptions that surround it. This latest article by Genomics' Co-Founder and CEO, Sir Peter Donnelly, discusses the common misunderstandings around genetic risk testing and the untapped benefits it holds for the insurance industry.

The three-year extension expands the range of therapeutic areas and genomic data insights and also explores the use of genomic risk to better define patient subgroups

We are proud to unveil new findings about our Integrated Risk Tool for cardiovascular disease, which has just achieved another significant validation. A recent study led by the University of Leicester, published in the esteemed European Heart Journal, underscores the transformative potential of our tool in early prevention.

The collaboration, across multiple therapeutic areas, will evaluate how polygenic risk scores could be used to improve clinical trial design and efficiency